Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.30 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733449 | 1.00 | TYMP (0.33) | TYMPP2RY14P2RY2P2RY4P2RY12 | |
| SCHEMBL31744952 | 0.98 | TYMP (0.33) | TYMPP2RY14P2RY2P2RY4P2RY12 | |
| SCHEMBL30733461 | 0.98 | TYMP (0.33) | TYMPP2RY14P2RY2P2RY4P2RY12 | |
| SCHEMBL31744991 | 0.97 | TYMP (0.32) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL31744944 | 0.94 | TYMP (0.32) | TYMPP2RY14P2RY2P2RY4 | |
| SCHEMBL6933190 | 0.94 | TYMP (0.35) | TYMPP2RY14P2RY2P2RY4P2RY12 | |
| SCHEMBL6932021 | 0.94 | TYMP (0.35) | TYMPP2RY14P2RY2P2RY4P2RY12 | |
| SCHEMBL6933255 | 0.91 | TYMP (0.36) | TYMPP2RY14P2RY2P2RY4P2RY12 | |
| SCHEMBL31744920 | 0.90 | TYMP (0.33) | TYMPP2RY14P2RY2P2RY4P2RY12 | |
| SCHEMBL3927922 | 0.90 | TYMP (0.37) | TYMPP2RY14P2RY2P2RY4P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4547852-A2 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024006953-A2 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | POLM, PCNA, POLRMT | TYMP 83/4885P2RY14 3785/4885P2RY2 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.